Skip to main content
. 2023 Nov 30;14(11):786. doi: 10.1038/s41419-023-06302-0

Fig. 3. Sorafenib downregulates DDX5 in preclinical HCC models.

Fig. 3

A–C Huh7 xenografts. NRG mice bearing Huh7 tumors were treated daily with 40 mg/kg sorafenib (SOR) for 1 week followed by 80 mg/kg SOR for 2 weeks (+) or DMSO (−) for 20 days. A DDX5 immunoblots from Huh7 tumors ± SOR, as indicated. Quantification of DDX5 protein levels from immunoblots by ImageJ software. Error bars represent SD from eight tumors. ***p < 0.001 by unpaired t-test. Actin is used as a loading control. B Quantification of DDX5 mRNA by qRT-PCR in tumors +/- SOR. Data are expressed as mean ± SEM from eight tumors. *p < 0.05 by unpaired t-test. C Tumor volume ± SOR normalized to day 0 of treatment. D–H HBx/c-myc mice. D Tumor growth was monitored by µCT scanner from each group, untreated (DMSO) and SOR-treated (60 mg/kg), as indicated. E Immunohistochemistry of formalin-fixed paraffin-embedded (FFPE) tumor and peri-tumor stained with DDX5 antibody, and counterstained with hematoxylin. F–H RT-qPCR detection of mRNA levels of DDX5 in (F, G) SOR-treated vs. untreated (DMSO) F tumors and G peri-tumoral tissue from HBx/c-Myc mice. *p < 0.05. H DDX5 mRNA level expressed as fold change between SOR-treated and untreated tumors and peri-tumoral tissue.